IMPower133 study The IMpower133 study has brought significant advancements in the treatment of advanced-stage small-cell lung cancer (ES-SCLC). By combining atezolizumab, a type of immunotherapy, wit...
Lung Cancer Treatment at Shanghai Pulmonary Hospital - A patient story In April 2025, Shanghai Pulmonary Hospital welcomed a special patient, Ms. Dietrich from the United States. In 2024, doctors dia...
On December 18, 2024, the Food and Drug Administration sanctioned ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or ...
On December 4, 2024, the Food and Drug Administration sanctioned durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose condition remains stable after...
On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for use in adults with specific conditions.Patients with advanced, unr...
On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy, succeeded b...
On September 25, 2024, the Food and Drug Administration sanctioned osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small ce...
On September 19, 2024, the Food and Drug Administration sanctioned amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in conjunction with carboplatin and pemetrexed for adult patients diagnosed with ...
On September 12, 2024, the Food and Drug Administration sanctioned atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous administration for all adult indications co...
Lung cancer vaccine The 'LungVax' vaccine, developed by researchers from the University of Oxford, the Francis Crick Institute, and University College London, employs technology akin to that of the v...